Introduction.
After the GH molecules are released by the pituitary in the blood stream, they are partially taken up and carried by binding proteins. The physiological role of this phenomenon could be the setting up of a GH reservoir and a GH sparing process since the metabolic clearance rate of the complex GH-binding protein is slower than that of free G H, thus increasing the biological half-life of the hormone.
Introduction.
Growth hormones (GH) represent a fascinating example of molecular evolution. With prolactins and placental lactogens (PL) also called chorionic somatomammotropins (CS) they are considered to belong to the same hormone super-family because in many species, and especially in humans, they share a number of biological, immunological and structural characteristics (Wallis, 1978 ; Nicoll, 1982) . The members of this family are derived from a common ancestral gene that diverged about 400 million years ago into the GH and the prolactin branches (Miller and Eberhardt, 1983) . However, human prolactin is thought to derive from a divergence of GH genes about 20 million years ago, while rat and ruminant prolactins would come from genes of the « prolactin » branch (Miller and Eberhardt, 1983) . Placental lactogen hormones probably appeared about 75 million years ago (Martal, 1980 ) from a duplication of the growth hormone cistron. Though most of the members of this hormone family have specific biological properties, some of them such as hGH (Li, 1972) , ovine PL Djiane, 1975, 1977 ; Martal, 1978) , bovine PL (Murthy et al., 1982) or primate PL (Josimovitch and Mac Laren, 1962; Friesen, 1965; Kaplan and Grumbach, 1965 ; Florini et al., 1966 ; Shome and Friesen, 1971 ) Primate GH is the only animal GH efficient in humans. However, the memory of its common ancestral origin with the GH of other species is found both in the high percentage of identical primary structures (table 1 ) and in the fact that certain fragments of non-human GH exert a more or less pronounced biological effect in humans (Liberti and Miller, 1978 ; Maciag et al., 1980 ; Hubbard and Liberti, 1980) . According to Kawauchi and Yasuda (1987) , GHs elicit four highly conserved domains through phylogenetic evolution ; these are aminoacid alignment positions (Guyda, 1975 ; Skyler et al., 1977) . Like (Singh et al., 1974a) .
Compared to the 22 K variant, the 24 K one retains its full immunological and growth-promoting activities (Lewis et al., 1980b) and has enhanced lactogenic activity (Chawla et al., 1983) .
This 24 K variant must not be confused with pituitary pre-GH (see above)
whose MW is also 24 Kd.
2) The 20 K variant. -The 20 K form is probably the most important variant of 22 K-hGH. It accounts for 10-15 % of the total pituitary store of hGH (Lewis etal., 1978) and up to 20 % of the G Hs released in a pituitary cell culture medium after 24-hour incubation (Markoff et al., 1986 (Closset et al., 1983) . A recent work of Smal et al. (1986) using isolated rat adipocytes (a target for the insulin-like effects of GH) and cultured IM-9 human lymphocytes (more specific for growth effects) shows that 20 K is a potent agonist of 22 K in the lymphocyte assay, while its potency in the adipocyte is only 3 %. In receptors from pregnant rabbit liver, 20 K also behaves like 22 K (Smal etal., 1987 (1985) showed that a naturally-occurring ovine GH was phosphorylated. This supposes the existence of a GH kinase. To date, other pituitary hormones lack phosphorylated forms. This suggests that the putative kinase is highly specific for GH or may be contained within somatotrophs and, therefore, that it is not accessible to the other hormones.
The same group also identified phosphorylated GH in rat anterior pituitary incubated in a 32 P i containing medium as well as in the medium itself. Gel filtration on Sephadex G-75, SDS-PAGE and autoradiography indicated that phosphorylated GH was synthesized and secreted by rat pituitary glands in vitro (Liberti and Joshi, 1986 (1983) .
2) Simian virus human growth hormone-2 (SV-hGH-2). -The gene coding for 22 K and 20 K is called hG H-N (see above). Another gene coding for a pre-G H form with 15 aminoacid substitutions (2 in the leader peptide and 13 distributed throughout the « mature » protein chain) was reported by Seeburg (1982) and called hGH-V. It is not known if this gene is normally expressed in pituitary, but it was expressed in a monkey kidney cell system by cloning in a simian virus (Pavlakis et al., 1981 ) . This new hGH molecule has an alkaline isoelectric pH of 8.9, mainly due to the loss of two acidic aminoacids and the benefit of three basic ones, suggesting that the alkaline forms (see above) found in pituitary extracts could be an expression of this newly-recognized gene. If this hGH-V gene was expressed in vivo, the synthesized product, SV-hGH-2, could account for the hGH species with high biological and weak immunological activities found in 80 K (see above) and some 22 K fractions (see charge variants). Moreover, SV-hGH-2 tends to aggregate. According to findings of the Hennen group in Belgium (Hennen etal., 1985b) , the hGH-V gene is actually expressed in vivo, at least in women, at the placental level to give rise to the newly-recognized human placental growth hormone, hPGH.
3) hGH 17.5 K. -In a recent work, Lecomte et al. (1987) , using a human pituitary cDNA library, reported that they have cloned three distinct hGH cDNAs, coding respectively for the well-known 22 K and 20 K forms and a yet unknown 17.5 K variant. The sequence of the concerned cDNA lacks the 120 bp corresponding to the entire third exon and encodes a protein of 17.5 Kd, a « truncated » hGH which lacks the 40 aminoacid residues coded by exon 3 and has never been reported in the literature. The biological features of this new putative hGH variant are still unknown. (Hennen etal., 1985a) . By means of two monoclonal I antibodies, specific either for an epitope, represented essentially by the Nterminal sequence of 22 K and 20 K, or for another one more internally located and absent in the 20 K, they were able to determine that pituitary secretion disappears after the 25th week of pregnancy. Simultaneously, from week 25 up to parturition, a GH-like material, restricted to maternal circulation and assumed to originate from the placenta, appears in the blood. This human placental GH (hPGH) disappears rapidly at delivery. hPGH most likely originates from the placenta as it is 10-fold more concentrated in this tissue than in serum (Hennen et al., 1985a) . It was extracted from that organ and then partially purified using ion-exchange and immunoaffinity chromatographies (Hennen et al., 1985b; Frankenne etal., 1987c) . hPGH was demonstrated to be more basic than pituitary GH, whose isoelectric point is around 5.5, and to be composed of two forms of 22 K and 25 K MW, respectively (Hennen et al., 1985b (Li and Ash, 1953 ; Wallis, 1969 Wallis, , 1973 Pena et al. (1969) showed that the origin of this variation was not allelic but probably arose from the ambiguous processing of a GH precursor. This N-terminal heterogeneity was also observed in oGH (Pena etal., 1970 (Kishida et al., 1987 
